How This Compares to Similar Drugs Tirzepatide's Phase 3 trials began in 2019, FDA submission happened in mid-2022, and approval came in May 2022 (for diabetes) and November 2023 (for obesity)
Generally, research in Epithalon has suggested its potential to preserve the overall structure of the eye and boost the retina's bioelectric function, which is deemed important for fully functional vision
Diabetologia 1977:13:145-52
Plus, a lot of compounding pharmacies will add additional elements like B12, because it kind of helps people feel better
Tirzepatide commonly causes nausea, vomiting, and appetite suppressioneffects that may compound with certain NAD supplements if they alter gut pH or motility
The science behind GHK-Cu and acne healing GHK-Cu has been extensively studied for its wound healing properties, making it a valuable tool in acne treatment